Single and multiple doses of Indacaterol, a novel once-daily β2-agonists, are well tolerated in patients with mild asthma

被引：0
|
作者：
Brookman, L
Knight, H
Wood, J
Perry, S
Tarral, A
Elharrar, B
Pascoe, S
机构：
[1] Novartis Horsham Res Ctr, Horsham, W Sussex, England
[2] Biotrial, Paris, France
[3] Aster Cephac, Paris, France
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2006年 / 117卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2005.12.333
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
324
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [31] Once-Daily vs. Twice-Daily Administration of Inhaled Budesonide for Mild and Moderate Well-Controlled Childhood Asthma: A Randomized, Controlled Trial
    Goyal, Megha
    Guglani, Vishal
    Kumar, Pankaj
    Randev, Shivani
    INDIAN JOURNAL OF PEDIATRICS, 2022, 89 (01): : 13 - 18
  • [32] Once-Daily vs. Twice-Daily Administration of Inhaled Budesonide for Mild and Moderate Well-Controlled Childhood Asthma: A Randomized, Controlled Trial
    Megha Goyal
    Vishal Guglani
    Pankaj Kumar
    Shivani Randev
    Indian Journal of Pediatrics, 2022, 89 : 13 - 18
  • [33] Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD:: A 28-day randomised, placebo controlled clinical trial
    Beier, Jutta
    Chanez, Pascal
    Martinot, Jean-Benoit
    Schreurs, A. J. M.
    Tkacova, Ruzena
    Bao, Weibin
    Jack, Damon
    Higgins, Mark
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (06) : 740 - 749
  • [34] Erratum to: Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases
    Kai M. Beeh
    Jutta Beier
    Advances in Therapy, 2009, 26 : 812 - 812
  • [35] Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma: post hoc pooled analysis from PALLADIUM and IRIDIUM studies
    Gon, Yasuhiro
    Ishii, Tsuyoshi
    Lawrence, David
    Nikolaev, Ivan
    Wang, Dong
    Sumi, Kazuya
    Nakamura, Yoichi
    JOURNAL OF ASTHMA, 2022, 59 (08) : 1627 - 1637
  • [36] Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
    Ohta, Ken
    Ichinose, Masakazu
    Tohda, Yuji
    Engel, Michael
    Moroni-Zentgraf, Petra
    Kunimitsu, Satoko
    Sakamoto, Wataru
    Adachi, Mitsuru
    PLOS ONE, 2015, 10 (04):
  • [37] Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA
    Bernstein, David
    Andersen, Leslie
    Forth, Richard
    Jacques, Loretta
    Yates, Louisa
    JOURNAL OF ASTHMA, 2018, 55 (09) : 984 - 993
  • [38] Ciclesonide once daily is well tolerated in children with mild, persistent asthma: a 1-year, double-blind, placebo-controlled study
    Maspero, J
    Malka, S
    Kundu, S
    Lloyd, M
    Banerji, D
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S94 - S94
  • [39] Trospium chloride once-daily extended release is effective and well tolerated in elderly patients (aged 75 years and over) with overactive bladder (OAB)
    Sand, P.
    Dmochowski, R.
    Rovner, E.
    Sandage, Jr B.
    Harnett, M.
    Ellsworth, P.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2008, 19 : S57 - S58
  • [40] Repeated once- and twice-daily doses of the novel multi-ligand somatostatin analog SOM230 are well tolerated
    Tran, LL
    Rothermel, J
    Reha, A
    PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2004, : 827 - 830
12345